Aeterna Zentaris (AEZS) and Hikma (HIK) ink Deal to Extend Market Reach to Middle East and North Africa
Aeterna Zentaris Inc. and Hikma Pharmaceuticals PLC today announced their exclusive commercialization and licensing agreement to register and market perifosine, Aeterna Zentaris' oral anti-cancer compound, in the Middle East and North Africa (MENA) region. Perifosine is currently in two phase 3 programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe. Today’s news reflects perifosine’s market potential for cancer treatment on a global scale. Juergen Engel, Ph.D., president and CEO of Aeterna Zentaris, noted Hikma’s position in the pharmaceutical market, as well as expectations for the collaborative agreement. "Hikma Pharmaceuticals has a proven track…